Literature DB >> 3198745

On the immunopathology of plaque development and repair in multiple sclerosis.

C S Raine1, L C Scheinberg.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3198745     DOI： 10.1016/0165-5728(88)90160-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


× No keyword cloud information.
  19 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 2.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

3.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

4.  GPR30 FORMS AN INTEGRAL PART OF E2-PROTECTIVE PATHWAY IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS.

Authors:  Sheetal Bodhankar; Halina Offner
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-12

5.  Lipid and fatty acid composition is altered in plaque tissue from multiple sclerosis brain compared with normal brain white matter.

Authors:  R Wilson; D R Tocher
Journal:  Lipids       Date:  1991-01       Impact factor: 1.880

Review 6.  Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.

Authors:  Jens Watzlawik; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2010-03       Impact factor: 4.618

7.  p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF.

Authors:  U Ladiwala; C Lachance; S J Simoneau; A Bhakar; P A Barker; J P Antel
Journal:  J Neurosci       Date:  1998-02-15       Impact factor: 6.167

Review 8.  TCR peptide therapy in human autoimmune diseases.

Authors:  A A Vandenbark; E Morgan; R Bartholomew; D Bourdette; R Whitham; D Carlo; D Gold; G Hashim; H Offner
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

Review 9.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 10.  Autologous T-cell vaccination for multiple sclerosis: a perspective on progress.

Authors:  Arthur A Vandenbark; Rivka Abulafia-Lapid
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.